Methyl 5-bromo-2-fluoronicotinate, 95.0%, 25g

4-Aminocyclohexaneethanol (cis- and trans- mixture)>98.0%(T)1g

(3-Ethynylphenyl)methanol, 97%, 1g

(S)-2-Amino-4-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(3-(dimethylamino)propyl)amino)butanoic acid 2,2,2-trifluoroacetic acid salt, 97%, 10mg

3-Methylthiophene>98.0%(GC)25g

N-Boc-2-Cyclohexyl-D-glycine, 97.0%, 5g

(2-(Benzyloxy)-4-(trifluoromethyl)phenyl)boronic acid, 98%, 5g

2-(2-Thienyl)ethyl p-Toluenesulfonate>95.0%(GC)5g

4-Nitro-p-terphenyl>95.0%(GC)5g

Methyl 4-amino-2-chloro-5-fluorobenzoate, 98%, 1g

(Z)-1-(4-Bromophenyl)-3-(4-chlorophenyl)propenone, 1g

Dde-L-Leu-ol, 98.0%, 250mg

Microliter syringe GASTIGHT® series 1700 Point type 2, 25 µl, 1702 RN, 1 piece